Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
RARE — Price & Forward EBITDA
Forward EBITDA (M)

Float Short %

10.88

Margin Of Safety %

Put/Call OI Ratio

0.81

EPS Next Q Diff

0.16

EPS Last/This Y

1.43

EPS This/Next Y

4.48

Price

23.15

Target Price

52.45

Analyst Recom

1.29

Performance Q

2.71

Upside

-982.9%

Beta

0.26

Ticker: RARE




21 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-03-09RARE22.580.830.0519686
2026-03-10RARE22.840.830.7219698
2026-03-11RARE22.210.830.1719718
2026-03-12RARE21.70.830.1619707
2026-03-13RARE21.710.830.1619707
2026-03-17RARE21.590.830.1719839
2026-03-18RARE20.450.80429.5019493
2026-03-19RARE20.41.100.9222771
2026-03-20RARE19.891.040.7022163
2026-03-23RARE20.261.040.7817044
2026-03-24RARE18.491.060.4717191
2026-03-25RARE19.850.770.0628933
2026-03-26RARE200.770.1829008
2026-03-27RARE19.370.760.0729123
2026-03-30RARE19.290.761.2529121
2026-03-31RARE20.940.760.0329127
2026-04-01RARE21.430.761.6429300
2026-04-02RARE22.440.767.9029341
2026-04-06RARE22.880.810.5830443
2026-04-07RARE23.160.810.0930652
2026-04-08RARE23.150.810.0430665
DateSymbolLatestP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-03-09RARE22.5910.2- -4.38
2026-03-10RARE22.8510.2- -4.38
2026-03-11RARE22.2110.2- -4.38
2026-03-12RARE21.6910.2- -4.38
2026-03-13RARE21.3310.2- -4.38
2026-03-17RARE21.599.2- -4.40
2026-03-18RARE20.449.2- -4.40
2026-03-19RARE20.419.2- -4.40
2026-03-20RARE19.879.2- -4.40
2026-03-23RARE20.279.2- -4.40
2026-03-24RARE18.509.2- -4.40
2026-03-25RARE19.849.2- -4.40
2026-03-26RARE19.989.2- -4.40
2026-03-27RARE19.389.2- -4.40
2026-03-30RARE19.299.2- -4.40
2026-03-31RARE20.939.2- -4.40
2026-04-01RARE21.429.2- -4.40
2026-04-02RARE22.459.2- -4.40
2026-04-06RARE22.879.2- -4.40
2026-04-07RARE23.179.2- -4.40
2026-04-08RARE23.159.2- -4.40
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-03-09RARE-2.23-2.9410.80
2026-03-10RARE-2.40-2.9410.80
2026-03-11RARE-2.40-2.9410.51
2026-03-12RARE-2.40-2.9410.51
2026-03-13RARE-2.35-2.9410.51
2026-03-17RARE-2.35-2.8310.51
2026-03-18RARE-2.35-2.8310.51
2026-03-19RARE-2.35-2.8310.51
2026-03-20RARE-2.35-2.8310.51
2026-03-23RARE-2.35-2.8310.51
2026-03-24RARE-2.35-2.8310.51
2026-03-25RARE-2.35-2.8310.88
2026-03-26RARE-2.35-2.8310.88
2026-03-27RARE-2.35-2.8310.88
2026-03-30RARE-2.35-2.8710.88
2026-03-31RARE-2.35-2.8710.88
2026-04-01RARE-2.35-2.8710.88
2026-04-02RARE-2.35-2.8710.88
2026-04-06RARE-2.43-2.9510.88
2026-04-07RARE-2.43-2.9510.88
2026-04-08RARE-2.43-2.9510.88
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-1.29

Avg. EPS Est. Current Quarter

-1.43

Avg. EPS Est. Next Quarter

-1.13

Insider Transactions

-2.43

Institutional Transactions

-2.95

Beta

0.26

Average Sales Estimate Current Quarter

163

Average Sales Estimate Next Quarter

179

Fair Value

Quality Score

24

Growth Score

48

Sentiment Score

49

Actual DrawDown %

80.6

Max Drawdown 5-Year %

-84

Target Price

52.45

P/E

Forward P/E

PEG

P/S

3.33

P/B

P/Free Cash Flow

EPS

-5.84

Average EPS Est. Cur. Y​

-4.4

EPS Next Y. (Est.)

0.08

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-85.54

Relative Volume

0.7

Return on Equity vs Sector %

691.5

Return on Equity vs Industry %

707.9

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.24

EBIT Estimation

RARE Healthcare
$23.15
📉
Swing / Pullback
Buy the dip on strong trends
50 /100
WEAK
Trend
14/20
Pullback
8/25
Volume
9/15
Valuation
12/20
TP/AR
2/10
Options
5/10
RSI
59.9
Range 1M
86.2%
Sup Dist
2.4%
🚀
Momentum Growth
Ride accelerating trends
N/A
35 /100
WEAK
Momentum
7/25
Growth
21/30
Estimates
1/20
Inst/Vol
1/15
Options
5/10
EPS Yr
27.7%
EPS NY
85.7%
52W%
20.2%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🔴 SELL -26.6% upside
Quality
7/30
Valuation
2/30
Growth
15/25
Stability
8/10
LT Trend
2/5
Upside
-26.6%
Quality
24
Ultragenyx Pharmaceutical Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 1371
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Solid Biosciences Inc.; Regeneron; Abeona; and Arcturus Therapeutics Holdings Inc. The company was incorporated in 2010 and is headquartered in Novato, California.
RARE

Latest News

Caricamento notizie per RARE
stock quote shares RARE – Ultragenyx Pharmaceutical Inc. Stock Price stock today
news today RARE – Ultragenyx Pharmaceutical Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RARE – Ultragenyx Pharmaceutical Inc. yahoo finance google finance
stock history RARE – Ultragenyx Pharmaceutical Inc. invest stock market
stock prices RARE premarket after hours
ticker RARE fair value insiders trading